Panbela Therapeutics Inc PBLA

Healthcare Biotechnology

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.

OTCQB:PBLA - Post by User

Panbela Therapeutics Inc > PBLA ....And just for the record.....

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Jan 26, 2024 2:38pm

82 Views

Post# 35847603

PBLA ....And just for the record.....

I still think that this will get another run before the close.

I'm not hanging around to see any carnage

Just my humble opinion.

Have a great weekend.......make sure you take a look at AVTX ; )

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide